Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

AstraZeneca Clinical Study Information Center 1-877-240-9479
information.center@astrazeneca.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
Back

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

Recruiting

Open to: ALL

Age: 18.0 - N/A

Cambridge Manchester Sutton London London Glasgow, Scotland Edgbaston London

Medical Conditions

Biliary Tract Neoplasms

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


A global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in participants with BTC after surgical resection with curative intent.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Dec 2023 Jun 2029

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Rilvegostomig IV (intravenous) Q3W

Intervention Arm Group : Arm A;

Intervention Type : DRUG
Intervention Description : Placebo IV (intravenous) Q3W

Intervention Arm Group : Arm B;

Intervention Type : DRUG
Intervention Description : Capecitabine (Oral) 1250 mg/m2 BID (twice daily) for 2 weeks on/1 week off in 21-day cycles or per local practice

Intervention Arm Group : Arm A;Arm B;

Intervention Type : DRUG
Intervention Description : Gemcitabine/Cisplatin IV (Intravenous) 1000 mg/m2 plus cisplatin 25 mg/m2 on Day 1 and Day 8 of each 21-day cycle

Intervention Arm Group : Arm A;Arm B;

Intervention Type : DRUG
Intervention Description : S-1 \[Tegafur/Oteracil/gimeracil\] (Oral) BSA (body surface area)-based (40, 50, or 60 mg) BID for 4 weeks on 2 weeks off in 42-day cycles

Intervention Arm Group : Arm A;Arm B;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Research Site
    Cambridge
    CB2 0QQ
  • Research Site
    Manchester
    M20 4BX
  • Research Site
    Sutton
    SM2 5PT
  • Research Site
    London
    NW3 2QG
  • Research Site
    London
    W12 0HS
  • Research Site
    Glasgow, Scotland
    G12 0YN
  • Research Site
    Edgbaston
    B15 2WB
  • Research Site
    London
    WC1E 6BT

AstraZeneca Clinical Study Information Center 1-877-240-9479
information.center@astrazeneca.com



The study is sponsored by AstraZeneca



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT06109779
Last updated 03 June 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top